|
| 37676819 | Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. | J Natl Cancer Inst | 2024 |
| 36115772 | Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. | Eur Urol | 2023 |
| 37812518 | A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer. | Clin Nucl Med | 2023 |
| 35798857 | Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2023 |
| 37290800 | SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-PSMA-617 Radionuclide Therapy. | J Nucl Med | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37055221 | Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin. | J Nucl Med | 2023 |
| 37247180 | Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. | J Neurooncol | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 36974724 | Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. | J Urol | 2023 |
| 37269841 | Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37070991 | A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. | Radiology | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37032186 | Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. | Eur Urol | 2023 |
| 36996380 | Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). | J Clin Oncol | 2023 |
| 36935345 | Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISEÂ V2). | Eur Urol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34593595 | Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. | J Nucl Med | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35504836 | Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). | Eur Urol Focus | 2022 |
| 35439030 | Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? | J Clin Oncol | 2022 |
| 35538298 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. | Prostate | 2022 |
| 35670774 | The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. | Clin Cancer Res | 2022 |
| 35759660 | Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. | Proc Natl Acad Sci U S A | 2022 |
| 35389387 | Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. | Clin Adv Hematol Oncol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35657341 | The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. | JNCI Cancer Spectr | 2022 |
| 36456108 | From Concept to Regulatory Drug Approval: Lessons for Theranostics. | J Nucl Med | 2022 |
| 35985981 | Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. | Eur Urol Oncol | 2022 |
| 35981096 | Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. | Science | 2022 |
| 34890060 | Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). | Cancer | 2022 |
| 35279418 | Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 35058323 | Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. | J Nucl Med | 2022 |
| 34903480 | Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. | Clin Genitourin Cancer | 2022 |
| 34965953 | Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). | Clin Cancer Res | 2022 |
| 34863587 | Inherited TP53 Variants and Risk of Prostate Cancer. | Eur Urol | 2022 |
| 34667026 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. | Clin Cancer Res | 2022 |
| 34597380 | Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. | J Natl Cancer Inst | 2022 |
| 32857839 | Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. | J Natl Cancer Inst | 2021 |
| 33744163 | Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer. | Eur Urol Focus | 2021 |
| 33622706 | Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. | Clin Cancer Res | 2021 |
| 33780276 | Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). | J Urol | 2021 |
| 33634707 | A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY). | J Urol | 2021 |
| 34936754 | Lutetium-177-PSMA-617 for Prostate Cancer. Reply. | N Engl J Med | 2021 |
| 34936753 | Lutetium-177-PSMA-617 for Prostate Cancer. | N Engl J Med | 2021 |
| 34767021 | Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. | JAMA Netw Open | 2021 |
| 34161051 | Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2021 |
| 34133209 | Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. | J Clin Oncol | 2021 |
| 34020931 | Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). | Eur Urol Oncol | 2021 |
| 33989025 | Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). | J Clin Oncol | 2021 |